RU2012124069A - Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин - Google Patents
Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин Download PDFInfo
- Publication number
- RU2012124069A RU2012124069A RU2012124069/15A RU2012124069A RU2012124069A RU 2012124069 A RU2012124069 A RU 2012124069A RU 2012124069/15 A RU2012124069/15 A RU 2012124069/15A RU 2012124069 A RU2012124069 A RU 2012124069A RU 2012124069 A RU2012124069 A RU 2012124069A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- insulin
- glp
- agonist
- liquid composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Abstract
1. Жидкая композиция, включающая агонист GLP-1 или/и его фармакологически приемлемую соль, инсулин или/и его фармакологически приемлемую соль и, необязательно, по меньшей мере одно фармацевтически приемлемое вспомогательное вещество, отличающаяся тем, что данная композиция содержит метионин.2. Жидкая композиция по п.1, отличающаяся тем, что содержит фармацевтически приемлемый консервант или/и фармацевтически приемлемое средство, обеспечивающее изотоничность.3. Жидкая композиция по п.1 или 2, отличающаяся тем, что содержит м-крезол или/и глицерин.4. Жидкая композиция по п.1, отличающаяся тем, что имеет значение pH от 3,5 до 5.5. Жидкая композиция по п.1, отличающаяся тем, что содержит метионин в количестве от 0,5 мг/мл до 20 мг/мл, в частности в количестве от 1 мг/мл до 5 мг/мл.6. Жидкая композиция по п.1, отличающаяся тем, что имеет после хранения в течение 6 месяцев при температуре +25°C химическую целостность.7. Жидкая композиция по п.1, отличающаяся тем, что имеет после хранения в течение 6 месяцев при температуре +25°C физическую целостность.8. Жидкая композиция по п.1, отличающаяся тем, что агонист GLP-1 выбирают из группы, состоящей из GLP-1 и его аналогов и производных, эксендина-3 и его аналогов и производных, эксендина-4 и его аналогов и производных, и при этом агонист GLP-1 предпочтительно выбирают из группы, которая состоит из:desProэксендин-4(1-39)-Lys-NHи эксендин-4.9. Жидкая композиция по п.1, при этом инсулин выбирают из инсулина человека, его аналогов, производных и метаболитов.10. Жидкая композиция по п.1, при этом инсулин выбирают из группы, которая состоит из Gly(A21)-Arg(B31)-Arg(B32)-инсулина человека, LysPro-инсулина человека, B28Asp инсулина человека и B29Lys(ε-тетра
Claims (28)
1. Жидкая композиция, включающая агонист GLP-1 или/и его фармакологически приемлемую соль, инсулин или/и его фармакологически приемлемую соль и, необязательно, по меньшей мере одно фармацевтически приемлемое вспомогательное вещество, отличающаяся тем, что данная композиция содержит метионин.
2. Жидкая композиция по п.1, отличающаяся тем, что содержит фармацевтически приемлемый консервант или/и фармацевтически приемлемое средство, обеспечивающее изотоничность.
3. Жидкая композиция по п.1 или 2, отличающаяся тем, что содержит м-крезол или/и глицерин.
4. Жидкая композиция по п.1, отличающаяся тем, что имеет значение pH от 3,5 до 5.
5. Жидкая композиция по п.1, отличающаяся тем, что содержит метионин в количестве от 0,5 мг/мл до 20 мг/мл, в частности в количестве от 1 мг/мл до 5 мг/мл.
6. Жидкая композиция по п.1, отличающаяся тем, что имеет после хранения в течение 6 месяцев при температуре +25°C химическую целостность.
7. Жидкая композиция по п.1, отличающаяся тем, что имеет после хранения в течение 6 месяцев при температуре +25°C физическую целостность.
8. Жидкая композиция по п.1, отличающаяся тем, что агонист GLP-1 выбирают из группы, состоящей из GLP-1 и его аналогов и производных, эксендина-3 и его аналогов и производных, эксендина-4 и его аналогов и производных, и при этом агонист GLP-1 предпочтительно выбирают из группы, которая состоит из:
desPro36эксендин-4(1-39)-Lys6-NH2 и эксендин-4.
9. Жидкая композиция по п.1, при этом инсулин выбирают из инсулина человека, его аналогов, производных и метаболитов.
10. Жидкая композиция по п.1, при этом инсулин выбирают из группы, которая состоит из Gly(A21)-Arg(B31)-Arg(B32)-инсулина человека, LysВ28ProВ29-инсулина человека, B28Asp инсулина человека и B29Lys(ε-тетрадеканоил),desB30 инсулина человека.
11. Жидкая композиция по п.1, отличающаяся тем, что содержит следующие компоненты:
(a) desPro36эксендин-4(1-39)-Lys6-NH2,
(b) Gly(A21)-Arg(B31)-Arg(B32)-инсулин человека,
(c) хлорид цинка,
(d) м-крезол (необязательно),
(e) L-метионин,
(f) глицерин,
(g) соляная кислота, в количестве, достаточном для получения значения pH примерно 4,5,
(h) раствор NaOH, в количестве достаточном для получения значения pH примерно 4,5, и
(i) вода.
12. Композиция по п.1, отличающаяся тем, что представляет собой композицию для инъекций.
13. Композиция по п.1 для лечения сахарного диабета.
14. Комбинация, включающая первую фармацевтическую композицию по одному из пп.1-13, вторую фармацевтическую композицию по одному из пп.1-13 и, необязательно, по меньшей мере одну следующую фармацевтическую композицию по одному из пп.1-13, каждая из которых содержит по меньшей мере один инсулин и по меньшей мере один агонист GLP-1, и по меньшей мере один инсулин или/и по меньшей мере один агонист GLP-1 содержатся в различных массовых долях по отношению к общей массе композиции.
15. Комбинация по п.14, при этом массовые доли по меньшей мере одного инсулина и по меньшей мере одного агониста GLP-1 в первой фармацевтической композиции, во второй фармацевтической композиции и в по меньшей мере одной, необязательной, следующей фармацевтической композиции выбирают таким образом, чтобы фармацевтические композиции имели различное отношение инсулина к агонисту GLP-1 в пересчете на массовые доли.
16. Комбинация по п.14 или 15, причем первая, вторая и. необязательно, следующая или следующие композиции содержат по меньшей мере один инсулин в, по существу, идентичных массовых долях, и по меньшей мере один агонист GLP-1 в различных массовых долях.
17. Комбинация по п.14 или 15, причем первая, вторая и, необязательно, следующая или следующие композиции содержат по меньшей мере один агонист GLP-1 в, по существу, идентичных массовых долях, а по меньшей мере один инсулин в различных массовых долях.
18. Набор, содержащий комбинацию по одному из пп.14-17.
19. Применение композиции по одному из пп.1-13, комбинации по пп.14-17 или набора по п.18 для получения лекарственного средства для лечения сахарного диабета.
20. Способ получения композиции по одному из пп.1-13, комбинации по пп.14-17 или набора по п.18, включающих композиции агониста GLP-1 или/и его фармакологически приемлемой соли с инсулином или/и его фармацевтически приемлемой солью, метионином и, необязательно, по меньшей мере одним фармацевтически приемлемым вспомогательным веществом.
21. Способ лечения пациентов композицией по одному из пп.1-13, комбинацией по пп.14-17 или набором по п.18, включающий введение композиции пациентам.
22. Применение композиции по одному из предшествующих пп.1-18, отличающееся тем, что оно происходит вместе с введением метформина, инсулина и/или агониста GLP-1 и/или фармакологически приемлемой соли.
23. Применение по п.22, отличающееся тем, что речь идет о дополнительной терапии, в частности к лечению инсулином и/или агонистом GLP-1.
24. Применение композиции по одному из пп.22 и 23, отличающееся тем, что терапию применяют у пациентов, которые не в достаточной мере могут контролировать диабет II типа с помощью инсулина и/или агониста GLP-1.
25. Применение композиции по одному из пп.1-18 в качестве дополнения к диете для того, чтобы контролировать уровень сахара в крови у пациентов с диабетом II типа, если показано применение инсулина или агониста GLP-1.
26. Применение композиции по одному из пп.22 или 23, отличающееся тем, что пациенты должны иметь значение HbA1c от 7% до 10%.
27. Применение композиция по одному из пп.22, 23 для лечения диабета II типа и/или ожирения.
28. Применение композиция по п.24 для лечения диабета II типа и/или ожирения.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102009052831 | 2009-11-13 | ||
DE102009052831.8 | 2009-11-13 | ||
DE102010020902.3 | 2010-05-18 | ||
DE102010020902 | 2010-05-18 | ||
PCT/EP2010/067250 WO2011058083A1 (de) | 2009-11-13 | 2010-11-11 | Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2012124069A true RU2012124069A (ru) | 2013-12-20 |
RU2537239C2 RU2537239C2 (ru) | 2014-12-27 |
Family
ID=43629454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012124069/15A RU2537239C2 (ru) | 2009-11-13 | 2010-11-11 | Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин |
Country Status (42)
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2229407T3 (pl) | 2008-01-09 | 2017-06-30 | Sanofi-Aventis Deutschland Gmbh | Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania |
PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
US20120232002A1 (en) * | 2009-07-06 | 2012-09-13 | Sanofi-Aventis Deutschland Gmbh | Slow-acting insulin preparations |
DK2451437T3 (en) * | 2009-07-06 | 2017-02-13 | Sanofi Aventis Deutschland | Aqueous INSULIN PREPARATIONS CONTAINING METHIONIN |
JP5973918B2 (ja) | 2009-11-13 | 2016-08-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Glp−1アゴニスト及びメチオニンを含む薬学的組成物 |
TR201809460T4 (tr) * | 2009-11-13 | 2018-07-23 | Sanofi Aventis Deutschland | Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim. |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病の治療用の医薬の製造のためのave0010の使用 |
KR20140041409A (ko) * | 2011-02-02 | 2014-04-04 | 사노피-아벤티스 도이칠란트 게엠베하 | 2형 진성 당뇨병 환자에서 저혈당증의 예방 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
US8901484B2 (en) * | 2012-04-27 | 2014-12-02 | Sanofi-Aventis Deutschland Gmbh | Quantification of impurities for release testing of peptide products |
EP2877197A2 (en) * | 2012-07-25 | 2015-06-03 | University Of Cincinnati | Method of treating type i diabetes using apolipoprotein aiv |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
EP2934569A1 (en) | 2012-12-21 | 2015-10-28 | Sanofi | Exendin-4 derivatives |
EP2945618B1 (en) * | 2013-01-17 | 2018-06-13 | vTv Therapeutics LLC | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
US10130288B2 (en) | 2013-03-14 | 2018-11-20 | Cell and Molecular Tissue Engineering, LLC | Coated sensors, and corresponding systems and methods |
US10405961B2 (en) | 2013-03-14 | 2019-09-10 | Cell and Molecular Tissue Engineering, LLC | Coated surgical mesh, and corresponding systems and methods |
DK2983697T3 (en) | 2013-04-03 | 2019-02-25 | Sanofi Sa | TREATMENT OF DIABETES MELLITUS WITH LONG-EFFECTIVE FORMULATIONS OF INSULIN |
TW201605489A (zh) * | 2013-10-25 | 2016-02-16 | 賽諾菲公司 | 賴谷胰島素(insulin glulisine)的穩定調配物 |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
CN105899191B (zh) | 2014-01-09 | 2020-06-16 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂 |
BR112016015851A2 (pt) | 2014-01-09 | 2017-08-08 | Sanofi Sa | Formulações farmacêuticas estabilizadas de insulina aspart |
MX2016008979A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. |
GB201401706D0 (en) * | 2014-01-31 | 2014-03-19 | Midatech Ltd | Nanoparticle-insulin and insulin analogue compositions |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
PL3139948T3 (pl) * | 2014-05-07 | 2020-08-10 | Novo Nordisk A/S | Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21 |
AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10413593B2 (en) * | 2014-10-24 | 2019-09-17 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and GLP-1 receptors |
CA2970200A1 (en) | 2014-12-12 | 2016-06-16 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
WO2018055539A1 (en) | 2016-09-22 | 2018-03-29 | Wockhardt Limited | Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue |
TWI774694B (zh) | 2016-09-23 | 2022-08-21 | 南韓商韓美藥品股份有限公司 | 具有降低對胰島素受體之親和力之胰島素類似物及其用途 |
AR111341A1 (es) | 2017-03-23 | 2019-07-03 | Hanmi Pharm Ind Co Ltd | Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo |
TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
GB201917723D0 (en) * | 2019-12-04 | 2020-01-15 | Nv Rose Llc | Stable liquid formulations of glucagon-like peptide 1 or analogues thereof |
WO2021142733A1 (en) * | 2020-01-16 | 2021-07-22 | Shanghai Benemae Pharmaceutical Corporation | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs |
WO2021142736A1 (en) * | 2020-01-16 | 2021-07-22 | Shanghai Benemae Pharmaceutical Corporation | Dosing regimen of glp-1 |
WO2022212271A1 (en) * | 2021-03-29 | 2022-10-06 | Sanford Health | Methods and compositions for treating lysosomal storage disorders |
Family Cites Families (392)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB835638A (en) | 1956-12-01 | 1960-05-25 | Novo Terapeutisk Labor As | Insulin crystal suspensions having a protracted effect |
GB840870A (en) | 1957-08-03 | 1960-07-13 | Novo Terapeutisk Labor As | Improvements in or relating to insulin preparations |
US3868358A (en) | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
US3758683A (en) | 1971-04-30 | 1973-09-11 | R Jackson | Insulin product |
US3984696A (en) | 1974-12-11 | 1976-10-05 | Medi-Ray, Inc. | Radiation guard for X-ray table |
US4153689A (en) | 1975-06-13 | 1979-05-08 | Takeda Chemical Industries, Ltd. | Stable insulin preparation for nasal administration |
GB1554157A (en) | 1975-06-13 | 1979-10-17 | Takeda Chemical Industries Ltd | Stable insulin preparation for intra nasal administration |
GB1527605A (en) | 1975-08-20 | 1978-10-04 | Takeda Chemical Industries Ltd | Insulin preparation for intranasal administration |
JPS6033474B2 (ja) | 1978-05-11 | 1985-08-02 | 藤沢薬品工業株式会社 | 新規なヒアルロニダ−ゼbmp−8231およびその製造法 |
US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
DE3064888D1 (en) | 1979-04-30 | 1983-10-27 | Hoechst Ag | Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization |
JPS55153712A (en) | 1979-05-18 | 1980-11-29 | Kao Corp | Insulin pharmaceutical preparation and its production |
DE3033127A1 (de) | 1980-09-03 | 1982-04-08 | Hoechst Ag, 6000 Frankfurt | Neue analoga des insulins |
US4367737A (en) | 1981-04-06 | 1983-01-11 | George Kozam | Multiple barrel syringe |
AU558474B2 (en) | 1981-07-17 | 1987-01-29 | Nordisk Insulinlaboratorium | A stable aqueous, therapeutic insulin preparation and a process for preparing it |
NL193099C (nl) | 1981-10-30 | 1998-11-03 | Novo Industri As | Gestabiliseerde insuline-oplossing. |
DE3326472A1 (de) | 1983-07-22 | 1985-02-14 | Hoechst Ag, 6230 Frankfurt | Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus |
DE3326473A1 (de) | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
DE3327709A1 (de) | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
DE3333640A1 (de) | 1983-09-17 | 1985-04-25 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung |
US4839341A (en) | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
CA1244347A (en) | 1984-05-29 | 1988-11-08 | Eddie H. Massey | Stabilized insulin formulations |
ATE50502T1 (de) | 1984-06-09 | 1990-03-15 | Hoechst Ag | Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung. |
DE3440988A1 (de) | 1984-11-09 | 1986-07-10 | Hoechst Ag, 6230 Frankfurt | Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung |
DK347086D0 (da) | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
DK113585D0 (da) | 1985-03-12 | 1985-03-12 | Novo Industri As | Nye peptider |
US5008241A (en) | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
IL78425A (en) | 1985-04-15 | 1991-05-12 | Lilly Co Eli | Intranasal formulation containing insulin |
US4689042A (en) | 1985-05-20 | 1987-08-25 | Survival Technology, Inc. | Automatic medicament ingredient mixing and injecting apparatus |
DE3526995A1 (de) | 1985-07-27 | 1987-02-05 | Hoechst Ag | Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
US4960702A (en) | 1985-09-06 | 1990-10-02 | Codon | Methods for recovery of tissue plasminogen activator |
DE3636903A1 (de) | 1985-12-21 | 1987-07-02 | Hoechst Ag | Fusionsproteine mit eukaryotischem ballastanteil |
DE3541856A1 (de) | 1985-11-27 | 1987-06-04 | Hoechst Ag | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens |
US5496924A (en) | 1985-11-27 | 1996-03-05 | Hoechst Aktiengesellschaft | Fusion protein comprising an interleukin-2 fragment ballast portion |
CA1275922C (en) | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
DE3544295A1 (de) | 1985-12-14 | 1987-06-19 | Bayer Ag | Thermoplastische formmassen mit hoher kriechstromfestigkeit |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
PH23446A (en) | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
IE62879B1 (en) | 1987-02-25 | 1995-03-08 | Novo Nordisk As | Novel insulin derivatives |
US5034415A (en) | 1987-08-07 | 1991-07-23 | Century Laboratories, Inc. | Treatment of diabetes mellitus |
DE3726655A1 (de) | 1987-08-11 | 1989-02-23 | Hoechst Ag | Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten |
DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
US6875589B1 (en) | 1988-06-23 | 2005-04-05 | Hoechst Aktiengesellschaft | Mini-proinsulin, its preparation and use |
DE3827533A1 (de) | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
US4923162A (en) | 1988-09-19 | 1990-05-08 | Fleming Matthew C | Radiation shield swivel mount |
DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
US5225323A (en) | 1988-11-21 | 1993-07-06 | Baylor College Of Medicine | Human high-affinity neurotransmitter uptake system |
KR910700262A (ko) | 1988-12-23 | 1991-03-14 | 안네 제케르 | 사람 인슐린 유사체 |
US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
PT93057B (pt) | 1989-02-09 | 1995-12-29 | Lilly Co Eli | Processo para a preparacao de analogos da insulina |
DK134189D0 (da) | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
ATE133087T1 (de) | 1989-05-04 | 1996-02-15 | Southern Res Inst | Einkapselungsverfahren |
US5006718A (en) | 1989-07-21 | 1991-04-09 | Lenhart Mark J | X-ray shield for X-ray examination table |
US5227293A (en) | 1989-08-29 | 1993-07-13 | The General Hospital Corporation | Fusion proteins, their preparation and use |
US5358857A (en) | 1989-08-29 | 1994-10-25 | The General Hospital Corp. | Method of preparing fusion proteins |
GR1005153B (el) | 1989-08-29 | 2006-03-13 | The General Hospital Corporation | Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους. |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
US5397771A (en) | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
DE69129110T2 (de) | 1990-05-10 | 1998-12-10 | Bechgaard Int Res | Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole |
DK155690D0 (da) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
DK10191D0 (da) | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
US5272135A (en) * | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
CA2038597A1 (en) | 1991-03-19 | 1992-09-20 | Jose P. Garzaran | A method and a pharmaceutical preparation for treating pain |
US5614219A (en) | 1991-12-05 | 1997-03-25 | Alfatec-Pharma Gmbh | Oral administration form for peptide pharmaceutical substances, in particular insulin |
US6468959B1 (en) | 1991-12-05 | 2002-10-22 | Alfatec-Pharm Gmbh | Peroral dosage form for peptide containing medicaments, in particular insulin |
CH682806A5 (de) | 1992-02-21 | 1993-11-30 | Medimpex Ets | Injektionsgerät. |
CH682805A5 (de) | 1992-02-24 | 1993-11-30 | Medimpex Ets | Anzeigeeinrichtung für ein Injektionsgerät. |
DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
US5846747A (en) | 1992-03-25 | 1998-12-08 | Novo Nordisk A/S | Method for detecting glucagon-like peptide-1 antagonists and agonists |
DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
US5253785A (en) | 1992-04-02 | 1993-10-19 | Habley Medical Technology Corp. | Variable proportion dispenser |
DK0600372T3 (da) | 1992-12-02 | 1997-08-11 | Hoechst Ag | Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer. |
AU680462B2 (en) | 1992-12-18 | 1997-07-31 | Eli Lilly And Company | Insulin analogs |
US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
US5478323A (en) | 1993-04-02 | 1995-12-26 | Eli Lilly And Company | Manifold for injection apparatus |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
WO1995000550A1 (en) | 1993-06-21 | 1995-01-05 | Novo Nordisk A/S | Aspb28 insulin crystals |
US5506203C1 (en) | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
US5534488A (en) | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
EP2275089A1 (en) | 1993-11-19 | 2011-01-19 | Alkermes Controlled Therapeutics, Inc. | Preparation of biodegradable microparticles containing a biologically active agent |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
IT1265271B1 (it) | 1993-12-14 | 1996-10-31 | Alcatel Italia | Sistema di predistorsione in banda base per la linearizzazione adattativa di amplificatori di potenza |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
DE4405179A1 (de) | 1994-02-18 | 1995-08-24 | Hoechst Ag | Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken |
DE4405388A1 (de) | 1994-02-19 | 1995-08-24 | Hoechst Ag | Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen |
WO1995024183A1 (en) | 1994-03-07 | 1995-09-14 | Inhale Therapeutic Systems | Methods and compositions for pulmonary delivery of insulin |
US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5559094A (en) | 1994-08-02 | 1996-09-24 | Eli Lilly And Company | AspB1 insulin analogs |
CA2196184C (en) | 1994-09-09 | 2009-06-09 | Yasutaka Igari | Sustained release preparation containing metal salt of a peptide |
US5879584A (en) | 1994-09-10 | 1999-03-09 | The Procter & Gamble Company | Process for manufacturing aqueous compositions comprising peracids |
US5547929A (en) | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
FR2724937B1 (fr) | 1994-09-28 | 1997-02-07 | Lvmh Rech | Polymeres fonctionnalises, leur procede de synthese, leur utilisation comme agents tensioactifs en particulier dans des compositions cosmetiques et notamment des vernis a ongles |
US5707641A (en) | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
YU18596A (sh) | 1995-03-31 | 1998-07-10 | Eli Lilly And Company | Analogne formulacije monomernog insulina |
US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
AU5724996A (en) | 1995-05-05 | 1996-11-21 | Eli Lilly And Company | Single chain insulin with high bioactivity |
US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
US6143718A (en) | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
AU6011496A (en) | 1995-06-08 | 1997-01-09 | Therexsys Limited | Improved pharmaceutical compositions for gene therapy |
AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
JPH11292787A (ja) | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
DE19637230A1 (de) | 1996-09-13 | 1998-03-19 | Boehringer Mannheim Gmbh | Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
DK0915910T3 (da) | 1996-06-05 | 2006-05-22 | Roche Diagnostics Gmbh | Exendin-analoger, fremgangsmåder til fremstilling deraf samt lægemidlter der indeholder disse |
BR9709844A (pt) | 1996-06-20 | 1999-08-10 | Novo Nordisk As | Preparação aquosa de insulina formulação farmacêutica parenteral usos de um carboidrato n o-redutor ou reduzido e de manitol sorbitol xilitol inositol trealose sacarose ou qualquer sua mistura e processo de fabricação de uma preparação de insulina |
US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
ATE208208T1 (de) | 1996-06-20 | 2001-11-15 | Novo Nordisk As | Halogenid-enthaltende insulinzubereitungen |
US6110703A (en) | 1996-07-05 | 2000-08-29 | Novo Nordisk A/S | Method for the production of polypeptides |
ES2319936T5 (es) | 1996-08-08 | 2013-06-24 | Amylin Pharmaceuticals, Inc. | Regulación de la motilidad gastrointestinal |
US5783556A (en) | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
US6384016B1 (en) | 1998-03-13 | 2002-05-07 | Novo Nordisk A/S | Stabilized aqueous peptide solutions |
US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
UA65549C2 (ru) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Применение аналогов и производных glp-1 для периферического введения для борьбы с ожирением |
DK0996459T3 (da) | 1997-01-07 | 2006-01-16 | Amylin Pharmaceuticals Inc | Anvendelse af exendiner og agonister deraf til reduktion af födeindtagelse |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
WO1998035033A1 (en) | 1997-02-05 | 1998-08-13 | 1149336 Ontario Inc. | Polynucleotides encoding proexendin, and methods and uses thereof |
US5846937A (en) | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
KR20000076419A (ko) | 1997-03-20 | 2000-12-26 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 폐 투여용 무아연 인슐린 결정 조성물 |
US6310038B1 (en) | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
US6043214A (en) | 1997-03-20 | 2000-03-28 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
AU740284B2 (en) | 1997-06-13 | 2001-11-01 | Genentech Inc. | Stabilized antibody formulation |
CO4750643A1 (es) | 1997-06-13 | 1999-03-31 | Lilly Co Eli | Formulacion estable de la insulina que contiene l-arginina y protamina |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
EP1019077B2 (en) | 1997-08-08 | 2010-12-22 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
DE19735711C2 (de) | 1997-08-18 | 2001-04-26 | Aventis Pharma Gmbh | Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken |
US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
KR20010024556A (ko) | 1997-10-24 | 2001-03-26 | 피터 지. 스트링거 | 불용성 인슐린 조성물 |
ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
DE69826705T2 (de) | 1997-11-12 | 2006-02-23 | Alza Corp., Palo Alto | Verfahren zur dermalen verabreichung von polypeptiden |
ATE383867T1 (de) | 1997-11-14 | 2008-02-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
DE69838916T2 (de) | 1997-11-14 | 2008-12-18 | Amylin Pharmaceuticals, Inc., San Diego | Neuartige exendin agonisten |
AU1617399A (en) | 1997-12-05 | 1999-06-28 | Eli Lilly And Company | Glp-1 formulations |
US5981964A (en) | 1997-12-22 | 1999-11-09 | Bruce J. McAuley | Adjustable X-ray shield and on-line dosimetry system using same |
EP1044016B1 (en) | 1998-01-09 | 2005-03-16 | Novo Nordisk A/S | Stabilised insulin compositions |
DE69936446T2 (de) | 1998-02-13 | 2008-03-06 | Amylin Pharmaceuticals, Inc., San Diego | Inotropische und diuretische effekte von exendin und glp-1 |
IL137904A0 (en) | 1998-02-23 | 2001-10-31 | Neurocrine Biosciences Inc | Peptide analogues of insulin and pharmaceutical compositions containing the same |
WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
EP1083930B1 (en) | 1998-06-05 | 2008-11-12 | Nutrinia Limited | Insulin supplemented infant formula |
US6410508B1 (en) | 1998-10-07 | 2002-06-25 | Med College Georgia Res Inst | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
DE69920767T2 (de) | 1998-10-16 | 2006-02-02 | Novo Nordisk A/S | Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung |
US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
CA2346884A1 (en) | 1998-10-16 | 2000-04-27 | Novo Nordisk A/S | Insulin preparations for pulmonary delivery containing menthol |
US6489292B1 (en) | 1998-11-18 | 2002-12-03 | Novo Nordisk A/S | Stable aqueous insulin preparations without phenol and cresol |
JP2002529514A (ja) | 1998-11-18 | 2002-09-10 | ノボ ノルディスク アクティーゼルスカブ | フェノール及びクレゾールを要さない安定なインスリン水性調製物 |
DE122007000001I1 (de) | 1999-01-14 | 2007-06-28 | Amylin Pharmaceuticals Inc | Neue exendin agonist Formulierungen und deren Verabreichung |
DE19908041A1 (de) | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Kovalent verbrückte Insulindimere |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
JP2007204498A (ja) | 1999-03-01 | 2007-08-16 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
JP2000247903A (ja) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
US6227819B1 (en) | 1999-03-29 | 2001-05-08 | Walbro Corporation | Fuel pumping assembly |
US6271241B1 (en) | 1999-04-02 | 2001-08-07 | Neurogen Corporation | Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors |
AU775063C (en) | 1999-04-30 | 2005-05-12 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
EA003922B1 (ru) | 1999-05-17 | 2003-10-30 | Конджачем, Инк. | Продолжительно действующие инсулинотропные пептиды |
AU5936400A (en) | 1999-06-04 | 2000-12-28 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
US6344180B1 (en) | 1999-06-15 | 2002-02-05 | Bionebraska, Inc. | GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes |
AU5760900A (en) | 1999-06-25 | 2001-01-31 | Minimed, Inc. | Multiple agent diabetes therapy |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
DE19930631A1 (de) | 1999-07-02 | 2001-01-11 | Clemens Micheler | Spritzvorrichtung zur Injektion mindestens zweier flüssiger Therapeutika, insbesondere Insuline |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
ATE296091T1 (de) | 1999-09-21 | 2005-06-15 | Skyepharma Canada Inc | Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe |
DE19947456A1 (de) | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga |
HU0800692D0 (en) | 1999-10-04 | 2009-01-28 | Novartis Vaccines & Diagnostic | Stabilized liquid polypeptide-containing pharmaceutical compositions |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
CA2389928C (en) | 1999-11-03 | 2010-03-23 | Bristol-Myers Squibb Company | Method for treating diabetes |
CN1409640A (zh) | 1999-12-16 | 2003-04-09 | 伊莱利利公司 | 稳定性改善的多肽组合物 |
EP1523993A1 (en) | 1999-12-16 | 2005-04-20 | Eli Lilly & Company | Polypeptide compositions with improved stability |
US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
WO2001051071A2 (en) | 2000-01-11 | 2001-07-19 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
US20010012829A1 (en) | 2000-01-11 | 2001-08-09 | Keith Anderson | Transepithelial delivery GLP-1 derivatives |
AU2001220765A1 (en) | 2000-01-24 | 2001-07-31 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
AU2001264789A1 (en) | 2000-06-08 | 2001-12-17 | Eli Lilly And Company | Protein powder for pulmonary delivery |
US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
DE60134251D1 (de) | 2000-09-18 | 2008-07-10 | Sanos Bioscience As | Verwendung von glp-2-peptiden |
KR100508695B1 (ko) | 2001-02-13 | 2005-08-17 | 한국과학기술연구원 | 인슐린의 경구투여용 제형과 그의 제조방법 |
US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
DE10108212A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände |
DE10108211A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen |
DE10108100A1 (de) | 2001-02-20 | 2002-08-29 | Aventis Pharma Gmbh | Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse |
US6852694B2 (en) * | 2001-02-21 | 2005-02-08 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
AU2002258428A1 (en) | 2001-02-26 | 2002-09-12 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of metabolic disorders, including obesity and diabetes |
DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
EP1377608B1 (en) | 2001-04-02 | 2009-09-16 | Novo Nordisk A/S | Insulin precursors and a process for their preparation |
CN1160122C (zh) | 2001-04-20 | 2004-08-04 | 清华大学 | 一种制备口服胰岛素油相制剂的方法 |
US20030026872A1 (en) | 2001-05-11 | 2003-02-06 | The Procter & Gamble Co. | Compositions having enhanced aqueous solubility and methods of their preparation |
US7156877B2 (en) | 2001-06-29 | 2007-01-02 | The Regents Of The University Of California | Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs |
FR2827604B1 (fr) | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
CA2455963C (en) | 2001-07-31 | 2017-07-04 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Glp-1, exendin-4, peptide analogs and uses thereof |
WO2003020201A2 (en) | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
US20050123509A1 (en) | 2001-10-19 | 2005-06-09 | Lehrman S. R. | Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
US20050013867A1 (en) | 2001-10-19 | 2005-01-20 | Lehrman S. Russ | Use of proton sequestering agents in drug formulations |
WO2003044210A2 (en) | 2001-11-19 | 2003-05-30 | Novo Nordisk A/S | Process for preparing insulin compounds |
EP1455815A4 (en) | 2001-12-19 | 2006-11-02 | Millennium Pharm Inc | MEMBERS OF THE DIACYLGLYCEROL-ACYLTRANSFERASES FAMILY 2 (DGAT2) AND USES THEREOF |
WO2003053339A2 (en) | 2001-12-20 | 2003-07-03 | Eli Lilly And Company | Insulin molecule having protracted time action |
HUP0402315A3 (en) | 2001-12-21 | 2009-03-30 | Novo Nordisk Healthcare Ag | Liquid composition of factor vii polypeptides |
US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
AU2003203146A1 (en) * | 2002-02-07 | 2003-09-02 | Novo Nordisk A/S | Use of glp-1 compound for treatment of critically ill patients |
US20100069293A1 (en) | 2002-02-27 | 2010-03-18 | Pharmain Corporation | Polymeric carrier compositions for delivery of active agents, methods of making and using the same |
TWI351278B (en) | 2002-03-01 | 2011-11-01 | Nisshin Pharma Inc | Agent for preventing and treating of liver disease |
JP2005526126A (ja) | 2002-05-07 | 2005-09-02 | ノボ ノルディスク アクティーゼルスカブ | インスリンアスパルト及びインスリンデテミアを含む可溶性製剤 |
EP1506230B1 (en) | 2002-05-07 | 2011-01-19 | Novo Nordisk A/S | Soluble formulations comprising monomeric insulin and acylated insulin |
US7115563B2 (en) | 2002-05-29 | 2006-10-03 | Insignion Holding Limited | Composition and its therapeutic use |
DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
ATE432289T1 (de) | 2002-07-04 | 2009-06-15 | Zealand Pharma As | Glp-1 und behandlungsmethode für diabetes |
DE10235168A1 (de) | 2002-08-01 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Verfahren zur Reinigung von Preproinsulin |
EP1539210A4 (en) * | 2002-09-06 | 2006-06-07 | Bayer Pharmaceuticals Corp | GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE |
EP1558237A4 (en) | 2002-09-27 | 2007-01-17 | Martek Biosciences Corp | IMPROVED GLYCEMIC REGULATION IN PREDIABETE AND / OR DIABETES TYPE II USING DOCOSAHEXAENOIC ACID |
MXPA05003335A (es) | 2002-10-02 | 2005-07-05 | Zealand Pharma As | Compuestos de exendina-4 estabilizados. |
US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
EP1583541B1 (en) | 2002-11-20 | 2011-01-12 | NeuroNova AB | Compounds and methods for increasing neurogenesis |
US20050209142A1 (en) | 2002-11-20 | 2005-09-22 | Goran Bertilsson | Compounds and methods for increasing neurogenesis |
CN1413582A (zh) | 2002-11-29 | 2003-04-30 | 贵州圣济堂制药有限公司 | 盐酸二甲双胍肠溶片及其制备方法 |
WO2004050115A2 (en) | 2002-12-03 | 2004-06-17 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
GB0309154D0 (en) | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
GB0304822D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
EA200501421A1 (ru) | 2003-03-04 | 2006-04-28 | Дзе Текнолоджи Девелопмент Компани Лтд. | Пероральная композиция инсулина и способы её изготовления и применения |
EP1610812A1 (en) | 2003-03-11 | 2006-01-04 | Novo Nordisk A/S | Pharmaceutical preparations comprising acid-stabilised insulin |
US20040186046A1 (en) | 2003-03-17 | 2004-09-23 | Pfizer Inc | Treatment of type 1 diabetes with PDE5 inhibitors |
DE10315408A1 (de) * | 2003-04-04 | 2004-10-14 | Robert Bosch Gmbh | Empfangseinheit und Verfahren zum Empfangen einer analoger Empfangssignale |
AU2004234345A1 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
MXPA05013048A (es) | 2003-06-03 | 2006-03-02 | Novo Nordisk As | Composiciones peptodicas farmaceuticas estabilizadas. |
DE10325567B4 (de) | 2003-06-05 | 2008-03-13 | Mavig Gmbh | Strahlenschutzanordnung mit separierbarer Umhüllung |
AU2004268648A1 (en) | 2003-08-29 | 2005-03-10 | Centocor, Inc. | Method of promoting graft survival with anti-tissue factor antibodies |
WO2005021022A2 (en) | 2003-09-01 | 2005-03-10 | Novo Nordisk A/S | Stable formulations of peptides |
WO2005023291A2 (en) | 2003-09-11 | 2005-03-17 | Novo Nordisk A/S | Use of glp1-agonists in the treatment of patients with type i diabetes |
TW200522976A (en) * | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
JP4800959B2 (ja) * | 2003-11-13 | 2011-10-26 | ノヴォ ノルディスク アー/エス | 糖尿病及び過食症を治療するためのglp−1ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物 |
US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
US20050201978A1 (en) | 2003-11-17 | 2005-09-15 | Lipton James S. | Tumor and infectious disease therapeutic compositions |
JP2007515235A (ja) | 2003-12-22 | 2007-06-14 | ノボ・ノルデイスク・エー/エス | 医薬液を保存するための、透明で、可撓性且つ不浸透性のプラスチック製容器 |
US20060210614A1 (en) | 2003-12-26 | 2006-09-21 | Nastech Pharmaceutical Company Inc. | Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
EP1701714A2 (en) | 2004-01-07 | 2006-09-20 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
US20070027063A1 (en) | 2004-01-12 | 2007-02-01 | Mannkind Corporation | Method of preserving the function of insulin-producing cells |
US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
US20080248999A1 (en) * | 2007-04-04 | 2008-10-09 | Biodel Inc. | Amylin formulations |
EP1750754A4 (en) | 2004-03-31 | 2010-09-22 | Centocor Ortho Biotech Inc | HUMAN GLP-1 MIMETIC BODIES, COMPOSITIONS, METHODS AND USES |
AU2005245240B2 (en) | 2004-05-20 | 2010-04-29 | Scimar Ltd. | Use of drug combinations for treating insulin resistance |
EA012281B1 (ru) | 2004-06-01 | 2009-08-28 | Арес Трейдинг С.А. | Способ стабилизации белков |
MXPA06014574A (es) | 2004-06-24 | 2007-03-12 | Incyte Corp | Piperidinas n-sustituidas y su uso como farmaceuticos. |
US20090042781A1 (en) | 2004-06-28 | 2009-02-12 | Novo Nordisk A/S | Methods for Treating Diabetes |
AU2005327906B2 (en) | 2004-07-21 | 2010-05-13 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
CN101010425B (zh) | 2004-08-13 | 2010-05-26 | 霍夫曼-拉罗奇有限公司 | 多肽的c-末端修饰 |
DE102004043153B4 (de) | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Erfindung betreffend GLP-1 und Exendin |
US20060073213A1 (en) | 2004-09-15 | 2006-04-06 | Hotamisligil Gokhan S | Reducing ER stress in the treatment of obesity and diabetes |
US20080280814A1 (en) | 2004-09-17 | 2008-11-13 | Novo Nordisk A/S | Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide |
ES2575984T3 (es) | 2004-11-12 | 2016-07-04 | Novo Nordisk A/S | Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal |
PL1817048T3 (pl) | 2004-11-12 | 2014-07-31 | Novo Nordisk As | Stabilne preparaty peptydów insulinotropowych |
DE102004058306A1 (de) | 2004-12-01 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden |
SE0402976L (sv) | 2004-12-03 | 2006-06-04 | Mederio Ag | Medicinsk produkt |
US20070128193A1 (en) | 2004-12-22 | 2007-06-07 | O'neil Karyn T | GLP-1 agonists, compositions, methods and uses |
US7879361B2 (en) | 2005-01-04 | 2011-02-01 | Gp Medical, Inc. | Nanoparticles for drug delivery |
EP2505207B1 (en) * | 2005-01-14 | 2015-04-22 | Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. | Modified exendins and uses thereof |
US7957939B2 (en) | 2005-02-01 | 2011-06-07 | Canberra Industries, Inc. | Maximum entropy signal detection method |
US20090142338A1 (en) | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
EP1909824B1 (en) | 2005-04-08 | 2011-05-18 | Amylin Pharmaceuticals, Inc. | Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent |
CN101180081B (zh) | 2005-05-25 | 2015-08-26 | 诺沃-诺迪斯克有限公司 | 稳定的多肽制剂 |
ES2399645T3 (es) | 2005-06-06 | 2013-04-02 | Camurus Ab | Formulaciones de análogos de GLP-1 |
JP5416969B2 (ja) | 2005-06-27 | 2014-02-12 | ニュートゥリー カンパニー リミテッド | メイスリグナンを利用してpparにより媒介される疾患を予防及び治療する方法 |
US20080227847A1 (en) | 2005-07-07 | 2008-09-18 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
JP4616105B2 (ja) * | 2005-07-20 | 2011-01-19 | 株式会社 日立ディスプレイズ | 液晶表示装置 |
MX2008002370A (es) | 2005-08-19 | 2008-04-29 | Amylin Pharmaceuticals Inc | Exendina para tratar la diabetes y reducir el peso del cuerpo. |
JP2009507050A (ja) | 2005-09-08 | 2009-02-19 | ガストロテック・ファルマ・アクティーゼルスカブ | 胆道ジスキネジーおよび/または胆道痛/不快の治療のためのglp−1分子の使用 |
BRPI0616054B8 (pt) | 2005-09-14 | 2021-05-25 | Sanofi Aventis Deutschland | processo para a preparação de insulina, um análogo de insulina ou um derivado de insulina, tripsina porcina, método para sua produção, dna e vetor |
PT1928499E (pt) | 2005-09-20 | 2011-09-09 | Novartis Ag | Utilização de um inibidor da dpp-iv para reduzir eventos hipoglicémicos |
WO2007038540A1 (en) | 2005-09-26 | 2007-04-05 | Medtronic, Inc. | Prosthetic cardiac and venous valves |
DE102005046113A1 (de) | 2005-09-27 | 2007-03-29 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen |
KR101105871B1 (ko) | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
WO2007044867A2 (en) | 2005-10-11 | 2007-04-19 | Huntington Medical Research Institutes | Imaging agents and methods of use thereof |
ATE518430T1 (de) | 2005-10-24 | 2011-08-15 | Nestec Sa | Rohfaserformulierung und verfahren zu ihrer verabreichung |
US20090214657A1 (en) | 2005-11-30 | 2009-08-27 | Muhammad Waseem Tahir Qazi | Orally Absorbed Pharmaceutical Formulation and Method of Administration |
US20100029558A1 (en) | 2005-12-06 | 2010-02-04 | Bristow Cynthia L | Alpha1 proteinase inhibitor peptides methods and use |
JP5096363B2 (ja) | 2005-12-16 | 2012-12-12 | ネクター セラピューティックス | Glp−1のポリマ複合体 |
US8178495B2 (en) | 2008-06-27 | 2012-05-15 | Duke University | Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide |
JP2009523129A (ja) | 2006-01-05 | 2009-06-18 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | 神経系を標的する薬理学的物質の性質を改善することに関連する方法および組成物 |
US8343914B2 (en) | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
US20090324701A1 (en) * | 2006-01-20 | 2009-12-31 | Diamedica, Inc. | Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders |
US20070191271A1 (en) | 2006-02-10 | 2007-08-16 | Dow Pharmaceutical Sciences | Method for stabilizing polypeptides lacking methionine |
EP1986674A4 (en) | 2006-02-13 | 2009-11-11 | Nektar Therapeutics | PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME |
WO2007098479A2 (en) | 2006-02-21 | 2007-08-30 | University Of Medicine And Dentistry Of New Jersey | Localized insulin delivery for bone healing |
EP1996224B1 (en) * | 2006-03-15 | 2012-11-07 | Novo Nordisk A/S | Mixtures of amylin and insulin |
TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
WO2007113205A1 (en) | 2006-04-03 | 2007-10-11 | Novo Nordisk A/S | Glp-1 peptide agonists |
CN101454019A (zh) | 2006-04-12 | 2009-06-10 | 百达尔公司 | 速效和长效胰岛素联合制剂 |
MX2008013168A (es) | 2006-04-13 | 2008-10-27 | Sod Conseils Rech Applic | Composiciones faramaceuticas del peptido 1 similar al glucagon humano, exendina-4 y análogos de los mismos. |
EP2021368A4 (en) | 2006-06-08 | 2010-01-20 | Diabecore Medical Inc | INSULIN OLIGOMERS DERIVED |
DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
JP2009544716A (ja) | 2006-07-27 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | 肺送達のためのインスリン含有エアロゾル化可能製剤 |
US7411757B2 (en) * | 2006-07-27 | 2008-08-12 | Hitachi Global Storage Technologies Netherlands B.V. | Disk drive with nonvolatile memory having multiple modes of operation |
WO2008021560A2 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Dpp-iv resistant gip hybrid polypeptides with selectable properties |
US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
EP2213289A1 (en) | 2006-09-07 | 2010-08-04 | Nycomed GmbH | Combination treatment for diabetes mellitus |
ES2601839T3 (es) | 2006-09-22 | 2017-02-16 | Novo Nordisk A/S | Análogos de insulina resistentes a proteasas |
DK2157967T3 (da) * | 2007-04-23 | 2013-04-08 | Intarcia Therapeutics Inc | Suspensionsformuleringer af insulinotropiske peptider og anvendelser deraf |
WO2008145323A1 (en) | 2007-05-31 | 2008-12-04 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for interferons |
ES2386166T5 (es) | 2007-06-14 | 2016-06-21 | Sanofi-Aventis Deutschland Gmbh | Carpule de dos cámaras con accesorio |
JP2010528792A (ja) | 2007-06-14 | 2010-08-26 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 二重チャンバーカルプル |
US7615480B2 (en) * | 2007-06-20 | 2009-11-10 | Lam Research Corporation | Methods of post-contact back end of the line through-hole via integration |
DK2173407T3 (da) | 2007-07-02 | 2020-04-27 | Hoffmann La Roche | Anordning til indgivelse af lægemiddel |
AU2008287063B2 (en) | 2007-08-09 | 2013-10-24 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
ES2558930T3 (es) | 2007-08-13 | 2016-02-09 | Novo Nordisk A/S | Análogos de la insulina de acción rápida |
CN101366692A (zh) | 2007-08-15 | 2009-02-18 | 江苏豪森药业股份有限公司 | 一种稳定的艾塞那肽制剂 |
GB0717388D0 (en) | 2007-09-07 | 2007-10-17 | Uutech Ltd | Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission |
GB0717399D0 (en) | 2007-09-07 | 2007-10-17 | Uutech Ltd | Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission |
WO2009033789A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
AU2008320844B2 (en) | 2007-11-01 | 2013-08-29 | Merck Serono S.A. | LH liquid formulations |
WO2009060071A1 (en) | 2007-11-08 | 2009-05-14 | Novo Nordisk A/S | Insulin derivative |
EP2209800B1 (en) | 2007-11-16 | 2013-07-24 | Novo Nordisk A/S | Stable pharmaceutical compositions comprising liraglutide and degludec |
CN101444618B (zh) | 2007-11-26 | 2012-06-13 | 杭州九源基因工程有限公司 | 含有艾塞那肽的药物制剂 |
WO2009075859A2 (en) * | 2007-12-11 | 2009-06-18 | Conjuchem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
WO2009089181A1 (en) | 2008-01-04 | 2009-07-16 | Blodel, Inc. | Insulin formulations for insulin release as a function of tissue glucose levels |
DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
PL2229407T3 (pl) * | 2008-01-09 | 2017-06-30 | Sanofi-Aventis Deutschland Gmbh | Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania |
DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
CA2711752A1 (en) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
AU2009211331B2 (en) | 2008-02-08 | 2014-07-03 | Theramex HQ UK Limited | Liquid formulation of FSH |
US8343140B2 (en) | 2008-02-13 | 2013-01-01 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
RU2495131C2 (ru) | 2008-02-19 | 2013-10-10 | Байокон Лимитид | Способ получения рекомбинантного инсулина гларгина |
TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
EP2288918A1 (en) | 2008-05-23 | 2011-03-02 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist bioassays |
TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
JP5854836B2 (ja) | 2008-08-30 | 2016-02-09 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | カートリッジ及びそのための針システム |
WO2010028055A1 (en) | 2008-09-02 | 2010-03-11 | Biodel, Inc. | Insulin with a basal release profile |
EP2684570A1 (en) | 2008-09-10 | 2014-01-15 | F. Hoffmann-La Roche AG | Compositions and methods for the prevention of oxidative degradation of proteins |
CN101670096B (zh) | 2008-09-11 | 2013-01-16 | 杭州九源基因工程有限公司 | 含有艾塞那肽的药物制剂 |
NZ592113A (en) | 2008-10-15 | 2012-04-27 | Intarcia Therapeutics Inc | Highly concentrated drug particles, formulations, suspensions and uses thereof |
PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
DE102008053048A1 (de) | 2008-10-24 | 2010-04-29 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
RU2540922C2 (ru) | 2008-10-30 | 2015-02-10 | Ново Нордиск А/С | Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день |
JP2009091363A (ja) | 2008-11-21 | 2009-04-30 | Asahi Kasei Pharma Kk | Pthの安定化水溶液注射剤 |
DK2393412T3 (en) | 2009-02-04 | 2017-12-11 | Sanofi Aventis Deutschland | MEDICAL DEVICE AND PROCEDURE FOR PROVIDING Glycemic Control Information |
KR20160143897A (ko) | 2009-02-13 | 2016-12-14 | 베링거 인겔하임 인터내셔날 게엠베하 | Dpp-4 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제 |
US20120231022A1 (en) | 2009-05-28 | 2012-09-13 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist compounds for sleep enhancement |
JP2012532177A (ja) | 2009-07-06 | 2012-12-13 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 熱及び振動安定性インスリン製剤 |
US20120232002A1 (en) * | 2009-07-06 | 2012-09-13 | Sanofi-Aventis Deutschland Gmbh | Slow-acting insulin preparations |
DK2451437T3 (en) * | 2009-07-06 | 2017-02-13 | Sanofi Aventis Deutschland | Aqueous INSULIN PREPARATIONS CONTAINING METHIONIN |
US8709400B2 (en) | 2009-07-27 | 2014-04-29 | Washington University | Inducement of organogenetic tolerance for pancreatic xenotransplant |
UA108475C2 (ru) | 2009-07-31 | 2015-05-12 | Санофі-Авентіс Дойчланд Гмбх | Композиция инсулина длительного действия |
WO2011017554A2 (en) | 2009-08-07 | 2011-02-10 | Mannkind Corporation | Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
US20110118178A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
JP5973918B2 (ja) * | 2009-11-13 | 2016-08-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Glp−1アゴニスト及びメチオニンを含む薬学的組成物 |
HUE026489T2 (en) | 2009-11-13 | 2016-06-28 | Sanofi Aventis Deutschland | Combination of lixisenatide and metformin to treat type 2 diabetes |
US20110118180A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
TR201809460T4 (tr) * | 2009-11-13 | 2018-07-23 | Sanofi Aventis Deutschland | Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim. |
DK2329848T4 (da) | 2009-11-13 | 2019-09-09 | Sanofi Aventis Deutschland | Lixisenatid som supplerende behandling til insulin glargin og metformin til behandling af type 2-diabetes |
WO2011075623A1 (en) | 2009-12-18 | 2011-06-23 | Latitude Pharmaceuticals, Inc. | One - phase gel compos ition compri s ing phos pholi pids |
EP2359843A1 (en) | 2010-01-21 | 2011-08-24 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
JP2013520175A (ja) | 2010-02-22 | 2013-06-06 | ケース ウェスタン リザーブ ユニバーシティ | 可溶形および結晶形の長時間作用型インスリン類似体製剤 |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
UY33326A (es) | 2010-04-14 | 2011-12-01 | Sanofi Aventis | Conjugados de insulina-sirna |
US8637458B2 (en) | 2010-05-12 | 2014-01-28 | Biodel Inc. | Insulin with a stable basal release profile |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
WO2011144674A2 (en) | 2010-05-20 | 2011-11-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD |
EP2389945A1 (en) | 2010-05-28 | 2011-11-30 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical composition comprising AVE0010 and insulin glargine |
US9085757B2 (en) | 2010-06-17 | 2015-07-21 | Regents Of The University Of Minnesota | Production of insulin producing cells |
US8532933B2 (en) | 2010-06-18 | 2013-09-10 | Roche Diagnostics Operations, Inc. | Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers |
US20130137645A1 (en) | 2010-07-19 | 2013-05-30 | Mary S. Rosendahl | Modified peptides and proteins |
JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病の治療用の医薬の製造のためのave0010の使用 |
SI2632478T1 (sl) | 2010-10-27 | 2019-11-29 | Novo Nordisk As | Zdravljenje sladkorne bolezni z uporabo inzulinskih injekcij, ki se dajejo v različnih injicirnih intervalih |
WO2012065996A1 (en) | 2010-11-15 | 2012-05-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN |
WO2012066086A1 (en) | 2010-11-17 | 2012-05-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN |
WO2012080320A1 (en) | 2010-12-14 | 2012-06-21 | Novo Nordisk A/S | Fast-acting insulin in combination with long-acting insulin |
KR20140041409A (ko) | 2011-02-02 | 2014-04-04 | 사노피-아벤티스 도이칠란트 게엠베하 | 2형 진성 당뇨병 환자에서 저혈당증의 예방 |
JP6170840B2 (ja) | 2011-03-11 | 2017-07-26 | ベス イスラエル デアコネス メディカル センター インコーポレイテッド | 抗cd40抗体及びその使用 |
US20120277147A1 (en) | 2011-03-29 | 2012-11-01 | Sanofi-Aventis Deutschland Gmbh | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
MX362527B (es) | 2011-05-13 | 2019-01-23 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. |
US8735349B2 (en) | 2011-05-13 | 2014-05-27 | Sanofi-Aventis Deutschland Gmbh | Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
US20130040878A1 (en) | 2011-05-13 | 2013-02-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |
US20140220134A1 (en) | 2011-06-24 | 2014-08-07 | Astrazeneca Pharamceuticals LP | Method for treating diabetes with extended release formulation of glp-1 receptor agonists |
AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
WO2013050379A1 (en) | 2011-10-04 | 2013-04-11 | Sanofi-Aventis Deutschland Gmbh | Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system |
US20130096059A1 (en) | 2011-10-04 | 2013-04-18 | Jens Stechl | Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract |
CN107693783A (zh) | 2011-10-28 | 2018-02-16 | 赛诺菲-安万特德国有限公司 | 2型糖尿病的治疗方案 |
US8901484B2 (en) | 2012-04-27 | 2014-12-02 | Sanofi-Aventis Deutschland Gmbh | Quantification of impurities for release testing of peptide products |
US9522235B2 (en) | 2012-05-22 | 2016-12-20 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
GB201303771D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticles peptide compositions |
JP6438944B2 (ja) | 2013-06-17 | 2018-12-19 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン/リキシセナチド固定比率製剤 |
TW201605489A (zh) | 2013-10-25 | 2016-02-16 | 賽諾菲公司 | 賴谷胰島素(insulin glulisine)的穩定調配物 |
-
2010
- 2010-11-11 TR TR2018/09460T patent/TR201809460T4/tr unknown
- 2010-11-11 NZ NZ599848A patent/NZ599848A/xx unknown
- 2010-11-11 BR BR112012011128A patent/BR112012011128A2/pt not_active Application Discontinuation
- 2010-11-11 PT PT181654377T patent/PT3417871T/pt unknown
- 2010-11-11 AR ARP100104183A patent/AR080669A1/es not_active Application Discontinuation
- 2010-11-11 PL PL18165437T patent/PL3417871T3/pl unknown
- 2010-11-11 UY UY0001033026A patent/UY33026A/es not_active Application Discontinuation
- 2010-11-11 KR KR1020187005718A patent/KR101972301B1/ko active IP Right Grant
- 2010-11-11 US US13/509,542 patent/US10029011B2/en active Active
- 2010-11-11 TW TW099138767A patent/TWI507190B/zh active
- 2010-11-11 PT PT107769986T patent/PT2498802E/pt unknown
- 2010-11-11 EP EP12190525.1A patent/EP2554183B1/de active Active
- 2010-11-11 ES ES18165437T patent/ES2855146T3/es active Active
- 2010-11-11 DK DK12190525.1T patent/DK2554183T3/en active
- 2010-11-11 EP EP20215294.8A patent/EP3831402A1/de active Pending
- 2010-11-11 JP JP2012538332A patent/JP5832439B2/ja active Active
- 2010-11-11 CN CN201710447024.5A patent/CN107308442B/zh active Active
- 2010-11-11 MX MX2012005186A patent/MX2012005186A/es active IP Right Grant
- 2010-11-11 ES ES12190525.1T patent/ES2676373T3/es active Active
- 2010-11-11 DK DK10776998T patent/DK2498802T3/en active
- 2010-11-11 CA CA3011480A patent/CA3011480C/en active Active
- 2010-11-11 EP EP18165437.7A patent/EP3417871B1/de active Active
- 2010-11-11 PL PL12190525T patent/PL2554183T3/pl unknown
- 2010-11-11 PL PL10776998T patent/PL2498802T3/pl unknown
- 2010-11-11 ES ES10776998.6T patent/ES2534191T3/es active Active
- 2010-11-11 RU RU2012124069/15A patent/RU2537239C2/ru active
- 2010-11-11 CA CA2780460A patent/CA2780460C/en active Active
- 2010-11-11 KR KR1020127015056A patent/KR101836070B1/ko active IP Right Grant
- 2010-11-11 EP EP10776998.6A patent/EP2498802B1/de active Active
- 2010-11-11 SI SI201031713T patent/SI2554183T1/en unknown
- 2010-11-11 LT LTEP12190525.1T patent/LT2554183T/lt unknown
- 2010-11-11 HU HUE12190525A patent/HUE038147T2/hu unknown
- 2010-11-11 AU AU2010317995A patent/AU2010317995B2/en active Active
- 2010-11-11 WO PCT/EP2010/067250 patent/WO2011058083A1/de active Application Filing
- 2010-11-11 PE PE2012000635A patent/PE20121362A1/es active IP Right Grant
- 2010-11-11 SI SI201030899T patent/SI2498802T1/sl unknown
- 2010-11-11 CN CN2010800614111A patent/CN102711805A/zh active Pending
- 2010-11-11 PT PT121905251T patent/PT2554183T/pt unknown
- 2010-11-11 MY MYPI2012001508A patent/MY180661A/en unknown
-
2012
- 2012-04-27 CR CR20120218A patent/CR20120218A/es unknown
- 2012-04-27 NI NI201200074A patent/NI201200074A/es unknown
- 2012-05-04 ZA ZA2012/03232A patent/ZA201203232B/en unknown
- 2012-05-10 IL IL219723A patent/IL219723A/en active IP Right Grant
- 2012-05-10 CO CO12077069A patent/CO6541565A2/es unknown
- 2012-05-10 MA MA34853A patent/MA33736B1/fr unknown
- 2012-05-10 DO DO2012000133A patent/DOP2012000133A/es unknown
- 2012-05-10 GT GT201200144A patent/GT201200144A/es unknown
- 2012-05-11 TN TNP2012000216A patent/TN2012000216A1/en unknown
- 2012-05-11 EC ECSP12011890 patent/ECSP12011890A/es unknown
- 2012-05-11 CL CL2012001232A patent/CL2012001232A1/es unknown
-
2013
- 2013-03-07 HK HK13102844.9A patent/HK1175409A1/xx unknown
-
2015
- 2015-03-30 HR HRP20150353TT patent/HRP20150353T1/hr unknown
- 2015-04-03 CY CY20151100320T patent/CY1116163T1/el unknown
-
2017
- 2017-05-23 HU HUS1700023C patent/HUS1700023I1/hu unknown
- 2017-06-22 LT LTPA2017020C patent/LTC2498802I2/lt unknown
- 2017-06-22 FR FR17C0004C patent/FR17C0004I2/fr active Active
- 2017-07-04 NO NO2017030C patent/NO2017030I2/no unknown
- 2017-07-06 CY CY2017023C patent/CY2017023I1/el unknown
- 2017-07-06 NL NL300883C patent/NL300883I2/nl unknown
- 2017-11-03 US US15/803,589 patent/US20180200370A1/en not_active Abandoned
-
2018
- 2018-07-03 HR HRP20181025TT patent/HRP20181025T1/hr unknown
- 2018-07-04 CY CY20181100699T patent/CY1120389T1/el unknown
-
2019
- 2019-10-28 US US16/666,000 patent/US20200188516A1/en not_active Abandoned
-
2021
- 2021-07-02 US US17/366,332 patent/US20220133890A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2012124069A (ru) | Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин | |
RU2012123739A (ru) | Фармацевтическая композиция, содержащая агонист гпп-1 и метионин | |
ES2772731T3 (es) | Combinación de una insulina y un agonista de GLP-1 | |
JP2012505852A5 (ru) | ||
RU2015132860A (ru) | Композиции инсулинов длительного действия | |
KR102231074B1 (ko) | 인슐린 글라진/릭시세나티드 고정비 제형 | |
RU2012103901A (ru) | Препарат инсулина, содержащий метионин | |
WO2012080320A1 (en) | Fast-acting insulin in combination with long-acting insulin | |
JP2012532179A5 (ru) | ||
US20150111820A1 (en) | Novel use of insulin derivatives | |
RU2015146982A (ru) | Лечение сахарного диабета с помощью составов инсулинов длительного действия | |
ES2724731T3 (es) | Composición farmacéutica | |
BRPI0920881B1 (pt) | Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo |